O-glycosylated clusterin as a sensitive marker for diagnosing early stages of prostate cancer.

BACKGROUND: Prostate-specific antigen (PSA) has been the most popular diagnostic marker for prostate cancer. The frequent occurrence of low PSA values (<10 ng/ml) in patients with highly suspicious prostate cancer, however, has undermined the accuracy of clinical examinations. The aim of this study was to develop a better resolution for diagnosing prostate cancer to overcome the disadvantage of PSA. METHODS: We focused on the glycosylation status of patients' serum proteins and conducted comprehensive lectin microarray analyses to characterize N- and O-glycans using sera from prostate cancer and benign prostatic diseases. Next, we retrieved candidate serum proteins with characteristic glycan structures using lectin-immobilized beads and identified them by quantitative mass spectrometry using a technique referred to as isobaric tag for relative and absolute quantitation (iTRAQ) labeling. Finally, we constructed a new assay to quantify a candidate glycoprotein with the newly identified glycans. RESULTS: Lectin microarray analyses revealed that sera from patients with prostate cancer had a higher affinity for Jacalin, Amaranthus caudatus (ACA) lectin, and Maclura pomifera (MPA) lectin, compared with that from patients with benign prostatic diseases and normal subjects, suggesting that O-glycosylated proteins are more abundant in sera from patients with prostate cancer. Then, serum glycoproteins preferentially adsorbed onto Jacalin-Agarose as well as biotin-ACA/and biotin-MPA/streptavidin-immobilized magnetic beads were isolated, labeled with iTRAQ, and identified using quantitative mass spectrometry. It was found that the ACA- and MPA-recognizable clusterin was more enriched in patients' sera from prostate cancer compared with those from benign prostatic diseases. Following this discovery, we constructed a Luminex-based assay to quantify O-glycosylated clusterin, in which total serum clusterin was first captured on anti-clusterin antibody-immobilized beads, and then clusterin-associated O-glycans were determined by the pair of biotin-MPA and streptavidin-phycoerythrin. When PSA values registered less than 10 ng/ml, the corresponding serum level of MPA-recognized clusterin determined by this assay was beneficial for distinguishing the patients with prostate cancer from the patients with benign prostatic disease. CONCLUSION: For PSA values that measure less than 10 ng/ml, the serum O-glycosylated clusterin level can be a complementary indicator for the malignancy of prostate cancer.

Vascular endothelial growth factor restores erectile function through modulation of the insulin-like growth factor system and sex hormone receptors in diabetic rat.

Previous studies have shown that intracavernous injection of vascular endothelial growth factor (VEGF) restored erectile function in diabetic rats. However, the mechanism of VEGF in diabetes-related erectile dysfunction (ED) has not been fully investigated. We hypothesize that intracavernous injection of VEGF may reverse diabetes-related ED through modulation of the insulin-like growth factor system and sex hormone receptors. To test this hypothesis the erectile function of treated and control rats was analyzed by measurement of intracavernous pressure (ICP) following electrostimulation of the cavernous nerves. Mean ICP was significantly lower in non-treated diabetic rats compared to controls. After VEGF injection, ICP was significantly higher than in non-treated diabetic rats. IGFBP-3 mRNA and protein expression was significantly higher in non-treated diabetic rat crura than controls, while VEGF-treated animals had control levels. ER-beta and PR mRNA and protein expression was significantly lower in non-treated diabetic rat crura. After VEGF injection, ER-beta and PR mRNA and protein expression was similar to control levels. Expression of AR and ER-alpha was the same in all groups. These findings suggest that orthotopic injection of VEGF may improve the functional recovery of diabetes-related ED through modulation of the insulin-like growth factor system and sex hormone receptors. To our knowledge, this is the first study demonstrating that VEGF treatment restores erectile function through restoration of the insulin-like growth factor system and sex hormone receptor genes at the mRNA and protein levels in diabetic rat crura. These results may be important in understanding the pathogenesis of diabetes-related ED and also in providing better strategies for management of this disease.

Loss of anti-apoptotic genes in aging rat crura.

PURPOSE: Erectile dysfunction is a common problem in aging men. The molecular mechanisms associated with aging erectile dysfunction are not completely understood. We hypothesized that apoptosis is a downstream event in erectile dysfunction, and pro-apoptotic (Bak and Bax) and anti-apoptotic (Bcl-2 and Bcl-x) factors are involved in the etiology of aging erectile dysfunction. To test this hypothesis intracavernous pressure in aging rats was measured to assess erectile function. Gene and protein expression of pro-apoptotic and anti-apoptotic factors was then analyzed in aging rat crura to assess its role in aging erectile dysfunction. MATERIALS AND METHODS: A total of 25 male Sprague-Dawley rats divided into 5 groups of 5 each based on age (6, 12, 18, 24 and 28 months old, respectively) were used in functional and apoptotic studies. In addition, 5, 3-month-old male Sprague-Dawley rats were used in the apoptotic study. The rats were anesthetized with pentobarbital. Erectile function was assessed by measuring intracavernous pressure after electrostimulation of the cavernous nerves. After completion of the functional study the penile crura were immediately harvested for histochemical and molecular studies. Gene expression of pro-apoptotic (Bak and Bax) and anti-apoptotic (Bcl-2 and Bcl-x) factors were then analyzed by reverse transcription-polymerase chain reaction. Protein expressions of these apoptotic factors were also analyzed by immunohistochemistry using specific antibodies. RESULTS: Mean intracavernous pressure plus or minus SD in 18, 24 and 28-month-old rats was significantly lower than in 6-month-old rats (101.6 +/- 24.8, 77.7 +/- 24.5 and 45.7 +/- 7.3 versus 136.7 +/- 11.4 cm. water, respectively; p <0.05). The reduction in intracavernous pressure was an age dependent phenomenon. Gene and protein expression of the pro-apoptotic genes Bak and Bax was detected in the crura of all age groups but there was no significant difference in young and old rat crura. The anti-apoptotic Bcl-2 and Bcl-x genes were expressed in 3, 6 and 12-month-old crura, whereas this expression was lost at 18, 24 and 28 months. Anti-apoptotic Bcl-2 and Bcl-x proteins were also expressed in young rat crura, whereas this expression was lost in old rat crura. CONCLUSIONS: The decline in intracavernous pressure correlated significantly with a loss of anti-apoptotic genes in aging rat crura. To our knowledge this is the first report to show the loss of anti-apoptotic factors in aging rat crura and suggest their role in the pathogenesis of aging erectile dysfunction.